Sanford C. Bernstein Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Key Points

• Analysts at Sanford C. Bernstein raised Regeneron Pharmaceuticals' price target from $753.00 to $781.00, suggesting a potential upside of 32.82% from its current price.
• The company reported $12.89 earnings per share in its latest quarterly earnings, exceeding analysts' expectations of $8.43 and reflecting a 3.6% increase in revenue compared to last year.
• Regeneron Pharmaceuticals has 83.31% of its stock owned by institutional investors, indicating strong support from large investors in the biopharmaceutical sector.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price target lifted by analysts at Sanford C. Bernstein from $753.00 to $781.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an "outperform" rating on the biopharmaceutical company's stock. Sanford C. Bernstein's target price would indicate a potential upside of 32.82% from the stock's current price.

REGN has been the subject of several other research reports. UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Jefferies Financial Group lifted their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a research report on Wednesday. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target for the company. in a research report on Friday, August 1st. Finally, Royal Bank Of Canada lifted their price target on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research report on Monday, August 4th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Trading Up 0.1%

NASDAQ:REGN traded up $0.38 during mid-day trading on Wednesday, hitting $588.03. 150,667 shares of the company's stock were exchanged, compared to its average volume of 1,107,302. The company has a 50 day simple moving average of $553.05 and a 200-day simple moving average of $589.45. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a fifty-two week low of $476.49 and a fifty-two week high of $1,210.97. The firm has a market capitalization of $62.32 billion, a P/E ratio of 14.80, a PEG ratio of 1.91 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3,675,600 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the business earned $11.56 EPS. The company's revenue was up 3.6% compared to the same quarter last year. As a group, research analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently modified their holdings of REGN. MASTERINVEST Kapitalanlage GmbH bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $1,138,000. Cim Investment Management Inc. grew its position in Regeneron Pharmaceuticals by 99.6% in the 2nd quarter. Cim Investment Management Inc. now owns 920 shares of the biopharmaceutical company's stock valued at $483,000 after acquiring an additional 459 shares during the last quarter. Monarch Capital Management Inc. grew its position in Regeneron Pharmaceuticals by 67.0% in the 2nd quarter. Monarch Capital Management Inc. now owns 2,345 shares of the biopharmaceutical company's stock valued at $1,231,000 after acquiring an additional 941 shares during the last quarter. Geneos Wealth Management Inc. grew its position in Regeneron Pharmaceuticals by 3.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 780 shares of the biopharmaceutical company's stock valued at $410,000 after acquiring an additional 23 shares during the last quarter. Finally, Westwood Holdings Group Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 17.0% in the 2nd quarter. Westwood Holdings Group Inc. now owns 13,556 shares of the biopharmaceutical company's stock worth $7,117,000 after buying an additional 1,974 shares during the period. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.